Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.

Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T.

J Dermatol. 2019 Dec 5. doi: 10.1111/1346-8138.15170. [Epub ahead of print]

PMID:
31803963
2.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

3.

Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study.

Shitara K, Honma Y, Omuro Y, Yamaguchi K, Chin K, Muro K, Nakagawa S, Kawakami S, Hironaka S, Nishina T.

Asia Pac J Clin Oncol. 2019 Nov 12. doi: 10.1111/ajco.13243. [Epub ahead of print]

PMID:
31721447
4.

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.

Shitara K, Hara H, Yoshikawa T, Fujitani K, Nishina T, Hosokawa A, Asakawa T, Kawakami S, Muro K.

Int J Clin Oncol. 2019 Oct 16. doi: 10.1007/s10147-019-01558-z. [Epub ahead of print]

PMID:
31620931
5.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Biomed Rep. 2019 Oct;11(4):171-180. doi: 10.3892/br.2019.1235. Epub 2019 Aug 21.

6.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.

Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I.

J Immunother Cancer. 2019 Aug 14;7(1):219. doi: 10.1186/s40425-019-0679-9.

7.

JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling.

Katagiri T, Yamazaki S, Fukui Y, Aoki K, Yagita H, Nishina T, Mikami T, Katagiri S, Shiraishi A, Kimura S, Tateda K, Sumimoto H, Endo S, Kameda H, Nakano H.

Mucosal Immunol. 2019 Sep;12(5):1104-1117. doi: 10.1038/s41385-019-0182-0. Epub 2019 Jul 8.

PMID:
31285535
8.

Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.

Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I.

Cancer Sci. 2019 Sep;110(9):2875-2883. doi: 10.1111/cas.14117. Epub 2019 Jul 23.

9.

Adventitial cystic disease of the popliteal artery with intimal tear.

Yada M, Sekine Y, Sato S, Nishina T.

J Cardiol Cases. 2019 Mar 8;19(6):197-199. doi: 10.1016/j.jccase.2019.02.003. eCollection 2019 Jun.

10.

Necroptosis of Intestinal Epithelial Cells Induces Type 3 Innate Lymphoid Cell-Dependent Lethal Ileitis.

Shindo R, Ohmuraya M, Komazawa-Sakon S, Miyake S, Deguchi Y, Yamazaki S, Nishina T, Yoshimoto T, Kakuta S, Koike M, Uchiyama Y, Konishi H, Kiyama H, Mikami T, Moriwaki K, Araki K, Nakano H.

iScience. 2019 May 31;15:536-551. doi: 10.1016/j.isci.2019.05.011. Epub 2019 May 14.

11.

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.

Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, Nishina T, Nakajima TE, Amagai K, Machida N, Goto M, Taku K, Wakatsuki T, Shoji H, Hironaka S, Boku N, Yamaguchi K.

Gastric Cancer. 2019 Nov;22(6):1238-1246. doi: 10.1007/s10120-019-00973-5. Epub 2019 May 17.

PMID:
31102009
12.

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).

Moriwaki T, Sakai Y, Ishida H, Yamamoto Y, Endo S, Kuramochi H, Sato M, Hatachi Y, Bando Y, Maeba T, Ikezawa K, Shimada M, Amagai K, Morimoto M, Kobayashi K, Tsuji A, Nishina T, Hyodo I.

Int J Clin Oncol. 2019 Oct;24(10):1214-1222. doi: 10.1007/s10147-019-01465-3. Epub 2019 May 14.

PMID:
31089842
13.

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.

Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, Yoshino T.

Br J Cancer. 2019 May;120(10):982-986. doi: 10.1038/s41416-019-0457-y. Epub 2019 Apr 24.

PMID:
31015557
14.

Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.

Haga H, Saito T, Okumoto K, Tomita K, Katsumi T, Mizuno K, Nishina T, Watanabe H, Ueno Y.

J Viral Hepat. 2019 Jul;26(7):866-872. doi: 10.1111/jvh.13099. Epub 2019 Apr 23.

PMID:
30924226
15.

[A Case of Laparoscopic Surgery Performed for Lynch Syndrome in a Patient Who Developed Cecal Cancer and Uterine Carcinosarcoma Synchronously].

Murakami T, Matsumoto T, Murashima N, Nishina T, Fujimoto Y, Sugiu K, Nagasaka T.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2042-2044. Japanese.

PMID:
30692278
16.

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.

Gastric Cancer. 2019 Mar;22(2):344-354. doi: 10.1007/s10120-018-0899-6. Epub 2018 Dec 1.

17.

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.

Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Watanabe M.

Gastric Cancer. 2019 Jul;22(4):817-827. doi: 10.1007/s10120-018-0903-1. Epub 2018 Dec 4.

18.

Current Cell-Based Therapies in the Chronic Liver Diseases.

Nishina T, Hoshikawa KT, Ueno Y.

Adv Exp Med Biol. 2018;1103:243-253. doi: 10.1007/978-4-431-56847-6_13. Review.

PMID:
30484233
19.

A murine model of acute lung injury identifies growth factors to promote tissue repair and their biomarkers.

Kurosawa T, Miyoshi S, Yamazaki S, Nishina T, Mikami T, Oikawa A, Homma S, Nakano H.

Genes Cells. 2019 Feb;24(2):112-125. doi: 10.1111/gtc.12659. Epub 2018 Dec 18.

20.

Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.

Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, Yoshino T.

Neoplasia. 2018 Dec;20(12):1219-1226. doi: 10.1016/j.neo.2018.10.004. Epub 2018 Nov 6.

21.

Is TEVAR with Full Petticoat Technique Effective for Complicated Acute Type B Dissection Cases?

Nishina T, Yoshida Y, Mizuno A, Yada M, Yamanaka K.

Ann Vasc Dis. 2018 Sep 25;11(3):350-354. doi: 10.3400/avd.cr.18-00020.

22.

Generation of and characterization of anti-IL-11 antibodies using newly established Il11-deficient mice.

Deguchi Y, Nishina T, Asano K, Ohmuraya M, Nakagawa Y, Nakagata N, Sakuma T, Yamamoto T, Araki K, Mikami T, Tanaka M, Nakano H.

Biochem Biophys Res Commun. 2018 Oct 28;505(2):453-459. doi: 10.1016/j.bbrc.2018.09.128. Epub 2018 Sep 26.

PMID:
30268501
23.

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.

Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A.

Clin Colorectal Cancer. 2018 Dec;17(4):e719-e732. doi: 10.1016/j.clcc.2018.07.009. Epub 2018 Jul 26.

24.

[Distortion Reduction Effect of View Angle Tilting (VAT) in Large Field of View Magnetic Resonance Imaging].

Nemoto H, Nagasaka T, Ota H, Yamashita Y, Nishina T, Machida Y.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(7):675-684. doi: 10.6009/jjrt.2018_JSRT_74.7.675. Japanese.

25.

Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.

Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I.

Gastric Cancer. 2019 Jan;22(1):138-146. doi: 10.1007/s10120-018-0845-7. Epub 2018 Jun 9.

PMID:
29948386
26.

[A case of relapsed neurosyphilis with progressive left hemiparesis].

Nishina T, Uemori M, Satou T, Asano A.

Rinsho Shinkeigaku. 2018 Jun 27;58(6):395-398. doi: 10.5692/clinicalneurol.cn-001063. Epub 2018 Jun 1. Japanese.

PMID:
29863099
27.

Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.

Yamaguchi K, Fujitani K, Nagashima F, Omuro Y, Machida N, Nishina T, Koue T, Tsujimoto M, Maeda K, Satoh T.

Gastric Cancer. 2018 Nov;21(6):1041-1049. doi: 10.1007/s10120-018-0811-4. Epub 2018 Mar 5.

PMID:
29508095
28.

[The Measurement Precision and Accuracy of T1 Mapping Using Polarity Corrected (PC) TI Prep Tool].

Ishikawa H, Seino S, Takasumi H, Kikori K, Harata M, Kanezawa T, Watanabe N, Satou T, Nishina T, Kuhara S.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(1):13-21. doi: 10.6009/jjrt.2018_JSRT_74.1.13. Japanese.

29.

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.

Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K.

Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30.

30.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.

Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.

31.

A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.

Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H.

Jpn J Clin Oncol. 2017 Nov 1;47(11):1002-1009. doi: 10.1093/jjco/hyx114.

PMID:
28973403
32.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

33.

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.

Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T.

Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30.

PMID:
28965185
34.

Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study.

Jingu K, Niibe Y, Yamashita H, Katsui K, Matsumoto T, Nishina T, Terahara A.

Radiat Oncol. 2017 Sep 5;12(1):146. doi: 10.1186/s13014-017-0882-0.

35.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T.

Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28.

PMID:
28760399
36.

Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.

Shitara K, Kadowaki S, Nishina T, Sakai D, Yoshikawa R, Piao Y, Ozeki A, Inoue K, Gritli I, Muro K.

Gastric Cancer. 2018 Jan;21(1):106-113. doi: 10.1007/s10120-017-0745-2. Epub 2017 Jun 30.

PMID:
28667466
37.

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.

Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W.

Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19.

PMID:
28404157
38.

Rare spinal cord infarction in a patient with acute type B aortic dissection.

Sekine Y, Nishina T, Ueda Y.

Interact Cardiovasc Thorac Surg. 2017 Jun 1;24(6):976-977. doi: 10.1093/icvts/ivx034.

PMID:
28329371
39.

Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients.

Yamashita H, Jingu K, Niibe Y, Katsui K, Matsumoto T, Nishina T, Terahara A.

Radiat Oncol. 2017 Feb 20;12(1):38. doi: 10.1186/s13014-017-0780-5.

40.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.

Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3.

41.

Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.

Yoshino T, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N.

Cancer Chemother Pharmacol. 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. Epub 2016 Dec 8.

PMID:
27933371
42.

Critical Contribution of Nuclear Factor Erythroid 2-related Factor 2 (NRF2) to Electrophile-induced Interleukin-11 Production.

Nishina T, Deguchi Y, Miura R, Yamazaki S, Shinkai Y, Kojima Y, Okumura K, Kumagai Y, Nakano H.

J Biol Chem. 2017 Jan 6;292(1):205-216. doi: 10.1074/jbc.M116.744755. Epub 2016 Nov 21.

43.

Novel method to rescue a lethal phenotype through integration of target gene onto the X-chromosome.

Sakata K, Araki K, Nakano H, Nishina T, Komazawa-Sakon S, Murai S, Lee GE, Hashimoto D, Suzuki C, Uchiyama Y, Notohara K, Gukovskaya AS, Gukovsky I, Yamamura KI, Baba H, Ohmuraya M.

Sci Rep. 2016 Nov 15;6:37200. doi: 10.1038/srep37200.

44.

Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.

Nishikawa K, Yamada Y, Ishido K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I.

Gastric Cancer. 2017 Jul;20(4):640-645. doi: 10.1007/s10120-016-0666-5. Epub 2016 Nov 7.

PMID:
27822684
45.

MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Katsumi T, Ninomiya M, Nishina T, Mizuno K, Tomita K, Haga H, Okumoto K, Saito T, Shimosegawa T, Ueno Y.

Lab Invest. 2016 Nov;96(11):1165-1177. doi: 10.1038/labinvest.2016.95. Epub 2016 Sep 26.

46.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.

Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098.

47.

100 °C Thermal Stability of Printable Perovskite Solar Cells Using Porous Carbon Counter Electrodes.

Baranwal AK, Kanaya S, Peiris TA, Mizuta G, Nishina T, Kanda H, Miyasaka T, Segawa H, Ito S.

ChemSusChem. 2016 Sep 22;9(18):2604-2608. doi: 10.1002/cssc.201600933. Epub 2016 Sep 15.

PMID:
27629068
48.

Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C.

Saito T, Sugimoto M, Okumoto K, Haga H, Katsumi T, Mizuno K, Nishina T, Sato S, Igarashi K, Maki H, Tomita M, Ueno Y, Soga T.

World J Gastroenterol. 2016 Jul 21;22(27):6224-34. doi: 10.3748/wjg.v22.i27.6224.

49.

Light stability tests of CH3NH3PbI3 perovskite solar cells using porous carbon counter electrodes.

Ito S, Mizuta G, Kanaya S, Kanda H, Nishina T, Nakashima S, Fujisawa H, Shimizu M, Haruyama Y, Nishino H.

Phys Chem Chem Phys. 2016 Oct 21;18(39):27102-27108. Epub 2016 Jul 12.

PMID:
27402555
50.

Late Sac Behavior after Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm.

Okada M, Handa N, Onohara T, Okamoto M, Yamamoto T, Shimoe Y, Yamashita M, Takahashi T, Kishimoto J, Mizuno A, Kei J, Nakai M, Sakaki M, Suhara H, Kasashima F, Endo M, Nishina T, Furuyama T, Kawasaki M, Iwata K, Marumoto A, Urata Y, Sato K, Ryugo M; National Hospital Organization Network Study Group for Abdominal Aortic Aneurysm in Japan.

Ann Vasc Dis. 2016;9(2):102-7. doi: 10.3400/avd.oa.15-00125. Epub 2016 Jun 2.

Supplemental Content

Loading ...
Support Center